ClinicalTrials.gg
CompletedNCT02203331Updated Nov 7, 2023Results posted

Bay98-7196, Dose Finding / POC Study

A Phase 2 interventional study of Placebo and Levonorgestrel in Endometriosis, sponsored by Bayer. Completed at 117 sites in 14 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by Bayer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
319
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Endometriosis by Bayer — none open to participants now, none under way, none of them phase 3. Endometriosis · Bayer.

Enrollment
Largest of 20
319 · median 68
Started
2014
the only one that year
Phase 2
6 of 27
none open now
Registered
10th of 27
by date

Among the 27 studies in Endometriosis by Bayer, this one has the largest enrollment of the 20 interventional ones that give a count, is the only one that started in 2014, is one of 6 in phase 2, and was the 10th registered.

Endometriosis

921 studies on the registry are indexed under Endometriosis; 267 are open to participants now.

Browse Endometriosis studies →

Open to participants now

None of the 27 studies in Endometriosis by Bayer is open now. The open studies under Endometriosis, anywhere →

Who these studies take

Of the 178 Endometriosis studies recruiting now, 52 (29%) set no upper age limit and 124 (70%) stop at 75 or younger; 18 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 27 studies in Endometriosis by Bayer as a file.
02

Study summary

Purpose of the study is to test efficacy and safety of BAY98-7196 intravaginal ring as a new treatment option for patients with endometriosis-associated pelvic pain

03

Conditions studied

  • Endometriosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Premenopausal women18 years and above at the time of screening.
  • Women with endometriosis confirmed by laparoscopy or laparotomy within the last ten years but not less than 8 weeks before the screening visit In Japan, diagnosis based on imaging (transvaginal ultrasound or MRI) also qualifies for inclusion.
  • Moderate to severe endometriosis-associated pelvic pain (EAPP) of ≥5 in the last 28 days before screening visit 1 measured on the numeric rating scale (NRS; i.e. 4-week recall period).
  • At randomization: Adherence to the study procedures during the screening period, at least 24 diary entries of ESD item 1 during the last 28 consecutive days before the randomization visit, and a sum of the available ESD item 1 ('worst pain' on the daily NRS) entries during this period of at least 98 (corresponding to an average score of ≥ 3.5).
  • Willingness to use only ibuprofen as rescue pain medication for EAPP, if needed according to investigator's instruction.
  • Use of a non-hormonal barrier method (i.e. spermicide-coated condoms) for from screening visit until the end of the study. This is not required if adequate contraception is achieved by vasectomy of the partner

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or lactation (less than three months since delivery, abortion, or lactation before start of treatment)
  • Any diseases or conditions that can compromise the function of the body systems and could result in altered absorption, excessive accumulation, impaired metabolism, or altered excretion of the study drug
  • Any diseases or conditions that might interfere with the conduct of the study or the interpretation of the results.
  • Any disease or condition that may worsen under hormonal treatment according to the assessment and opinion of the investigator.
  • Undiagnosed abnormal genital bleeding
  • Wish for pregnancy during the study
  • Regular use of pain medication due to other underlying diseases
  • Non-responsiveness of endometriosis associated pelvic pain (EAPP) to GnRH-a or surgery (partial response is not exclusionary).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
319 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

    Drug: Placebo

  • Experimental
    Levonorgestrel

    Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

    Drug: Placebo · Drug: Levonorgestrel

  • Experimental
    Anastrozole 300 µg/d + Levonorgestrel

    Anastrozole 300 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

    Drug: Placebo · Drug: Anastrozole

  • Experimental
    Anastrozole 600 µg/d + Levonorgestrel

    Anastrozole 600 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

    Drug: Placebo · Drug: Anastrozole

  • Experimental
    Anastrozole 1050 µg/d + Levonorgestrel

    Anastrozole 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

    Drug: Placebo · Drug: Anastrozole

  • Active comparator
    Lupron / Leuprolide acetate

    Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection

    Drug: Placebo · Drug: Lupron / Leuprolide acetate

Interventions

  • DrugPlacebo

    Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

  • Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

  • Participants received Anastrozole 300 µg/d or 600 µg/d or 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection

  • DrugLupron / Leuprolide acetate

    Drug page: Leuprolide

    Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection

06

What researchers measure

Primary outcomes

  1. Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days 57-84) as Measured on NRS by Question 1 of ESD

    Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, participants were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain of the 7 days with worst EAPP within a 28-day window was calculated as the sum of ESD item 1 on 7 days with worst EAPP within that 28-day window divided by 7.

    Time frame: Baseline (last 28 days before randomization), end of treatment (Treatment 3) (last 28 days of the treatment period, Day 57-84)

Secondary outcomes

  1. Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment (Day 1-28) and to Second Cycle Under Study Treatment (Day 29-56) as Measured on NRS by Question 1 of ESD

    Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain of the 7 days with worst EAPP within a 28-day window was calculated as the sum of ESD item 1 on 7 days with worst EAPP within that 28-day window divided by 7.

    Time frame: Baseline (last 28 days before randomization), first cycle (Treatment 1) (Day 1-28), second cycle (Treatment 2) (Day 29-56)

  2. Absolute Change in Mean Pain From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment(Day1-28), Second Cycle Under Study Treatment(Day29-56),Third Cycle Under Study Treatment (Day57-84) as Measured on NRS by Question1 of ESD

    Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain within a 28-day window was calculated as the sum of ESD item 1 within that 28-day window divided by the number with non-missing days within that 28-day window. Here, number of subjects 'n' signifies evaluable subjects for the respective category.

    Time frame: Baseline (last 28 days before randomization), first cycle (Treatment 1) (Day 1-28), second cycle (Treatment 2) (Day 29-56), and third cycle (Treatment 3) (last 28 days of the treatment period, Day 57-84)

  3. Percentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain Greater Than or Equal to (>=) 7 as Measured on NRS by Question 1 of ESD as Measured on NRS by Question 1 of ESD

    Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=7 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that 28-day window where item 1 of the ESD was \>=7.

    Time frame: Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)

  4. Change From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=7 as Measured on NRS by Question 1 of ESD

    Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=7 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that 28-day window where item 1 of the ESD was \>=7. Here, number of subjects 'n' signifies evaluable subjects for the respective category.

    Time frame: Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)

  5. Percentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain >=4 as Measured on NRS by Question 1 of ESD

    Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=4 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that window where Item 1 of the ESD was \>=4. Here, number of subjects 'n' signifies evaluable subjects for the respective category.

    Time frame: Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)

  6. Change From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=4 as Measured on NRS by Question 1 of ESD

    Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=4 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that window where Item 1 of the ESD was \>=4. Here, number of subjects 'n' signifies evaluable subjects for the respective category.

    Time frame: Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)

07

Results

Posted Jan 4, 2018

Participant flow

Study was conducted in fourteen countries in Austria, Belgium, Canada, Czech Republic, Denmark, Finland, Germany, Japan, Netherlands, Norway, Poland, Spain, Switzerland, United States, between 16 October 2014 (first participant first visit) and 24 October 2016 (last participant last visit).

Participant flow — Overall Study
MilestoneLNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo Injection
Started525355535353
Treated495054495053
Completed453950464646
Not completed7145777
Withdrew: Pregnancy100020
Withdrew: Withdrawal by subject101003
Withdrew: Adverse event483433
Withdrew: Other reasons120200
Withdrew: Lack of efficacy021001
Withdrew: Protocol violation020110
Withdrew: Lost to follow-up000010

Outcome measures

PrimaryAbsolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days 57-84) as Measured on NRS by Question 1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, participants were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain of the 7 days with worst EAPP within a 28-day window was calculated as the sum of ESD item 1 on 7 days with worst EAPP within that 28-day window divided by 7.

Time frame:
Baseline (last 28 days before randomization), end of treatment (Treatment 3) (last 28 days of the treatment period, Day 57-84)
Reported as:
Mean · units on a scale
Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days 57-84) as Measured on NRS by Question 1 of ESD
units on a scaleLNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo Injection
Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to End of Treatment (Last 28 Days of Treatment Period, Days 57-84) as Measured on NRS by Question 1 of ESD-1.8974 ± 1.6416-1.6061 ± 1.6652-2.4014 ± 2.1833-2.2653 ± 1.5972-3.7679 ± 2.3507-2.293 ± 1.8247
Statistical analysis
  • LNG 40 mcg IVR + Placebo Injection vs ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection vs Placebo IVR + Leuprorelin Injection · Contrast tests for dose-response model · p = 0.3875 · Emax: 0.1483
  • LNG 40 mcg IVR + Placebo Injection vs ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection vs Placebo IVR + Leuprorelin Injection · Contrast tests for dose-response model · p = 0.2676 · Linear: 0.2484
  • LNG 40 mcg IVR + Placebo Injection vs ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection vs Placebo IVR + Leuprorelin Injection · Contrast tests for dose-response model · p = 0.3211 · Sigmoidal emax 1: 0.1995
  • LNG 40 mcg IVR + Placebo Injection vs ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection vs Placebo IVR + Leuprorelin Injection · Contrast tests for dose-response model · p = 0.1721 · Sigmoidal emax 2: 0.3467
SecondaryAbsolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment (Day 1-28) and to Second Cycle Under Study Treatment (Day 29-56) as Measured on NRS by Question 1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain of the 7 days with worst EAPP within a 28-day window was calculated as the sum of ESD item 1 on 7 days with worst EAPP within that 28-day window divided by 7.

Time frame:
Baseline (last 28 days before randomization), first cycle (Treatment 1) (Day 1-28), second cycle (Treatment 2) (Day 29-56)
Reported as:
Mean · units on a scale
Absolute Change in Mean Pain of the 7 Days With Worst EAPP From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment (Day 1-28) and to Second Cycle Under Study Treatment (Day 29-56) as Measured on NRS by Question 1 of ESD
units on a scaleLNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo Injection
Change at Treatment 1-0.7582 ± 1.1518-0.6849 ± 1.3832-1.1463 ± 1.3992-1.0000 ± 1.2579-1.2071 ± 1.1978-0.9048 ± 1.1686
Change at Treatment 2-1.6447 ± 1.4831-1.5126 ± 2.0161-2.1224 ± 2.2791-1.9959 ± 1.3978-2.8607 ± 2.0665-1.8022 ± 1.5131
Statistical analysis
  • LNG 40 mcg IVR + Placebo Injection vs ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection vs Placebo IVR + Placebo Injection · Contrast tests for dose-response model · p = 0.231 · Emax: 0.2736
  • LNG 40 mcg IVR + Placebo Injection vs ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection vs Placebo IVR + Placebo Injection · Contrast tests for dose-response model · p = 0.1865 · Linear: 0.3234
  • LNG 40 mcg IVR + Placebo Injection vs ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection vs Placebo IVR + Placebo Injection · Contrast tests for dose-response model · p = 0.1955 · Sigmoidal emax 1: 0.3081
  • LNG 40 mcg IVR + Placebo Injection vs ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection vs Placebo IVR + Placebo Injection · Contrast tests for dose-response model · p = 0.1416 · Sigmoidal emax 2: 0.3781
SecondaryAbsolute Change in Mean Pain From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment(Day1-28), Second Cycle Under Study Treatment(Day29-56),Third Cycle Under Study Treatment (Day57-84) as Measured on NRS by Question1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The mean pain within a 28-day window was calculated as the sum of ESD item 1 within that 28-day window divided by the number with non-missing days within that 28-day window. Here, number of subjects 'n' signifies evaluable subjects for the respective category.

Time frame:
Baseline (last 28 days before randomization), first cycle (Treatment 1) (Day 1-28), second cycle (Treatment 2) (Day 29-56), and third cycle (Treatment 3) (last 28 days of the treatment period, Day 57-84)
Reported as:
Mean · units on a scale
Absolute Change in Mean Pain From Baseline (Last 28 Days Before Randomization) to First Cycle Under Study Treatment(Day1-28), Second Cycle Under Study Treatment(Day29-56),Third Cycle Under Study Treatment (Day57-84) as Measured on NRS by Question1 of ESD
units on a scaleLNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo Injection
Baseline6.0938 ± 1.53145.7409 ± 1.30446.3694 ± 1.53005.7128 ± 1.44156.3962 ± 1.45755.6399 ± 1.5312
Change at Treatment 1-0.8472 ± 1.1905-0.9009 ± 1.3434-1.0931 ± 1.4002-1.1257 ± 1.3317-1.5315 ± 1.4809-0.9777 ± 1.0680
Change at Treatment 2-1.5774 ± 1.6278-1.5068 ± 1.8707-1.7349 ± 1.9403-1.9615 ± 1.3966-2.6855 ± 2.0601-1.8994 ± 1.3069
Change at Treatment 3-1.8001 ± 1.7687-1.6411 ± 1.8071-2.0112 ± 1.9575-2.1268 ± 1.6877-3.502 ± 2.3096-2.2228 ± 1.4957
Statistical analysis
  • LNG 40 mcg IVR + Placebo Injection vs ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection vs Placebo IVR + Placebo Injection · Contrast tests for dose-response model · p = 0.5794 · Emax: 0.0081
  • LNG 40 mcg IVR + Placebo Injection vs ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection vs Placebo IVR + Placebo Injection · Contrast tests for dose-response model · p = 0.4301 · Linear: 0.1148
  • LNG 40 mcg IVR + Placebo Injection vs ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection vs Placebo IVR + Placebo Injection · Contrast tests for dose-response model · p = 0.5337 · Sigmoidal emax 1: 0.0401
  • LNG 40 mcg IVR + Placebo Injection vs ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection vs ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection vs Placebo IVR + Placebo Injection · Contrast tests for dose-response model · p = 0.3396 · Sigmoidal emax 2: 0.1835
SecondaryPercentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain Greater Than or Equal to (>=) 7 as Measured on NRS by Question 1 of ESD as Measured on NRS by Question 1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=7 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that 28-day window where item 1 of the ESD was \>=7.

Time frame:
Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)
Reported as:
Mean · percentage of days
Percentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain Greater Than or Equal to (>=) 7 as Measured on NRS by Question 1 of ESD as Measured on NRS by Question 1 of ESD
percentage of daysLNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo Injection
Treatment 135.6034 ± 34.312627.5659 ± 27.642640.0813 ± 37.269423.9322 ± 28.623428.2015 ± 28.843025.1742 ± 24.2811
Treatment 225.6257 ± 33.931522.8695 ± 28.344334.4364 ± 40.562314.9331 ± 23.802812.1320 ± 25.163814.1869 ± 17.7364
Treatment 323.1293 ± 33.945119.9332 ± 26.054029.8103 ± 39.043414.3362 ± 25.67708.5351 ± 20.781912.7574 ± 18.5154
SecondaryChange From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=7 as Measured on NRS by Question 1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=7 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that 28-day window where item 1 of the ESD was \>=7. Here, number of subjects 'n' signifies evaluable subjects for the respective category.

Time frame:
Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)
Reported as:
Mean · percentage of days
Change From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=7 as Measured on NRS by Question 1 of ESD
percentage of daysLNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo Injection
Change at Treatment 1-13.6756 ± 22.6822-12.5862 ± 21.4336-15.0341 ± 21.0071-13.3722 ± 19.6416-19.8898 ± 25.9273-16.0105 ± 19.0190
Change at Treatment 2-24.1404 ± 28.5082-17.2826 ± 29.0007-20.6791 ± 30.2152-22.3713 ± 24.4098-36.3540 ± 34.9706-26.9979 ± 24.9493
Change at Treatment 3-26.4197 ± 31.4648-20.8529 ± 28.3939-25.3052 ± 33.5497-22.9682 ± 28.8677-39.9516 ± 33.8277-28.4273 ± 29.6186
SecondaryPercentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain >=4 as Measured on NRS by Question 1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=4 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that window where Item 1 of the ESD was \>=4. Here, number of subjects 'n' signifies evaluable subjects for the respective category.

Time frame:
Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)
Reported as:
Mean · percentage of days
Percentage of Days During Baseline (Last 28 Days Before Randomization) and Cycles 1, 2, and 3 With Pain >=4 as Measured on NRS by Question 1 of ESD
percentage of daysLNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo Injection
Treatment 171.8037 ± 32.365869.3092 ± 27.864273.8956 ± 31.686870.6504 ± 27.852870.2066 ± 28.933365.9074 ± 30.0166
Treatment 261.8199 ± 37.121757.8777 ± 34.742962.5822 ± 37.698952.6028 ± 35.610654.0965 ± 38.962949.487 ± 31.3566
Treatment 360.2902 ± 37.858557.0171 ± 34.364256.7691 ± 40.380350.7332 ± 36.290338.6986 ± 39.604547.0976 ± 35.3227
SecondaryChange From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=4 as Measured on NRS by Question 1 of ESD

Pain intensity was assessed on 11-point (0-10) NRS by question 1. In question 1, subjects were asked to rate the pain in the target area during the past 24 hours, where 0= no pain and 10= worst imaginable pain and responses were recorded in ESD. The percentage of days with pain \>=4 within a 28-day window was calculated as 100 divided by the number of non-missing days within that 28-day window multiplied by the number of days within that window where Item 1 of the ESD was \>=4. Here, number of subjects 'n' signifies evaluable subjects for the respective category.

Time frame:
Baseline (last 28 days before randomization), Cycle 1 (Treatment 1), Cycle 2 (Treatment 2), and Cycle 3 (Treatment 3)
Reported as:
Mean · percentage of days
Change From Baseline (Last 28 Days Before Randomization) to Cycle 1, 2, and 3 in Percentage of Days With Pain >=4 as Measured on NRS by Question 1 of ESD
percentage of daysLNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo Injection
Change at Treatment 1-12.8228 ± 20.4330-15.4147 ± 24.0608-15.1334 ± 22.5347-15.1947 ± 21.1740-21.4331 ± 23.4546-14.5323 ± 20.9670
Change at Treatment 2-22.4950 ± 28.1535-26.8462 ± 32.6194-26.4468 ± 34.4661-33.2423 ± 27.3686-37.7330 ± 36.9484-30.9527 ± 25.4665
Change at Treatment 3-23.5498 ± 30.2853-27.4770 ± 34.2051-32.2600 ± 37.4997-35.1119 ± 30.9316-53.4266 ± 38.8452-33.3421 ± 25.7105

Adverse events

Collected over From start of study treatment up to 30 days after end of treatment (Day 114). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LNG 40 mcg IVR + Placebo Injection—2/49 (4.1%)38/49 (77.6%)
ATZ 300 mcg / LNG 40 mcg IVR + Placebo Injection—0/50 (0%)40/50 (80%)
ATZ 600 mcg / LNG 40 mcg IVR + Placebo Injection—0/54 (0%)40/54 (74.1%)
ATZ 1050 mcg / LNG 40 mcg IVR + Placebo Injection—2/49 (4.1%)35/49 (71.4%)
Placebo IVR + Leuprorelin Injection—3/50 (6%)35/50 (70%)
Placebo IVR + Placebo Injection—4/53 (7.5%)38/53 (71.7%)
Most frequent serious events
Most frequent serious events
EventLNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo Injection
EndometriosisReproductive system and breast disorders1/490/500/540/491/501/53
Ovarian cystReproductive system and breast disorders1/490/500/540/490/500/53
Haemorrhagic ovarian cystReproductive system and breast disorders0/490/500/541/490/500/53
Dyshidrotic eczemaSkin and subcutaneous tissue disorders0/490/500/541/490/500/53
Pregnancy of unknown locationPregnancy, puerperium and perinatal conditions0/490/500/540/491/500/53
HydronephrosisRenal and urinary disorders0/490/500/540/491/500/53
Renal atrophyRenal and urinary disorders0/490/500/540/491/500/53
PyelonephritisInfections and infestations0/490/500/540/490/501/53
MenorrhagiaReproductive system and breast disorders0/490/500/540/490/501/53
Pelvic painReproductive system and breast disorders0/490/500/540/490/501/53
Most frequent other events
Showing 10 of 211
Most frequent other events
EventLNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo Injection
Ovarian cystReproductive system and breast disorders20/4920/5024/5416/495/507/53
Hot flushVascular disorders1/490/503/543/4917/502/53
HeadacheNervous system disorders5/498/503/548/498/506/53
NasopharyngitisInfections and infestations2/492/507/545/491/503/53
AcneSkin and subcutaneous tissue disorders2/491/501/545/491/502/53
EndometriosisReproductive system and breast disorders3/492/503/542/492/505/53
Abdominal painGastrointestinal disorders0/491/501/544/490/500/53
NauseaGastrointestinal disorders2/492/502/544/493/503/53
Vaginal haemorrhageReproductive system and breast disorders1/493/502/544/490/500/53
Libido decreasedPsychiatric disorders0/491/501/540/494/500/53

Baseline characteristics

Age, Continuous
Age, Continuous(years)LNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo InjectionTotal
Mean33.27 ± 7.432.96 ± 8.7933.96 ± 5.7333.72 ± 7.8533.7 ± 6.2934.89 ± 7.1333.75 ± 7.23
Sex: Female, Male
Sex: Female, Male(Participants)LNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo InjectionTotal
Female525355535353319
Male0000000
Body Mass Index (BMI)
Body Mass Index (BMI)(kilogram per square meter (kg/m^2))LNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo InjectionTotal
Mean24.19 ± 4.5226.07 ± 6.7123.84 ± 6.1525.47 ± 5.6825.47 ± 5.5124.43 ± 5.0824.91 ± 5.67
Mean Pain of the 7 Days With Worst Endometriosis Associated Pelvic Pain (EAPP)
Mean Pain of the 7 Days With Worst Endometriosis Associated Pelvic Pain (EAPP)(units on a scale)LNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo InjectionTotal
Mean7.8205 ± 1.1717.4664 ± 0.98938.1905 ± 1.0687.5429 ± 1.25687.8964 ± 1.19527.6886 ± 1.23897.7842 ± 1.1702
Percentage of Days With Pain Greater Than or Equal to (>=) 7
Percentage of Days With Pain Greater Than or Equal to (>=) 7(percentage of days)LNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo InjectionTotal
Mean50.094 ± 35.520140.1521 ± 29.871455.1155 ± 33.762537.3044 ± 30.289448.7001 ± 33.668541.1847 ± 33.047945.8234 ± 33.1247
Percentage of Days With Pain >=4
Percentage of Days With Pain >=4(percentage of days)LNG 40 mcg IVR + Placebo InjectionATZ 300 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 600 mcg / LNG 40 mcg IVR + Placebo InjectionATZ 1050 mcg / LNG 40 mcg IVR + Placebo InjectionPlacebo IVR + Leuprorelin InjectionPlacebo IVR + Placebo InjectionTotal
Mean86.0058 ± 19.313684.7239 ± 18.171389.029 ± 16.366785.8451 ± 17.946692.9141 ± 11.600880.4397 ± 20.100486.6042 ± 17.6568
08

Study locations

117 sites
  • San Diego, California 92108, United States
  • San Francisco, California 94158-2509, United States
  • Gainesville, Florida 32605, United States
  • New Port Richey, Florida 34652, United States
  • Atlanta, Georgia 30338, United States
  • Sandy Springs, Georgia 30328, United States
  • Chicago, Illinois 60611, United States
  • Palos Heights, Illinois 60463, United States
  • Wichita, Kansas 67226, United States
  • Marrero, Louisiana 70072, United States
  • Canton, Michigan 48187, United States
  • Detroit, Michigan 48034, United States
  • Saginaw, Michigan 48604, United States
  • Lincoln, Nebraska 68510, United States
  • Neptune, New Jersey 07754, United States
  • Plainsboro, New Jersey 08536, United States
  • Durham, North Carolina 27713, United States
  • Greensboro, North Carolina 27408, United States
  • Winston-Salem, North Carolina 27103, United States
  • Columbus, Ohio 43213, United States
  • Dayton, Ohio 45409, United States
  • Philadelphia, Pennsylvania 19104, United States
  • Chattanooga, Tennessee 37404, United States
  • Seattle, Washington 98105, United States
  • Madison, Wisconsin 53562, United States
  • Villach, Kärnten 9500, Austria
  • Linz, Oberösterreich 4020, Austria
  • Innsbruck, Tirol 6020, Austria
  • Wien, 1090, Austria
  • Bruxelles - Brussel, 1000, Belgium
  • Bruxelles - Brussel, 1070, Belgium
  • Edegem, 2650, Belgium
  • Gent, 9000, Belgium
  • Hamilton, Ontario L8S 4K1, Canada
  • Ottawa, Ontario K1H 7W9, Canada
  • Toronto, Ontario M5C 2T2, Canada
  • Montreal, Quebec H4P 2S4, Canada
  • Quebec, G1S 2L6, Canada
  • Brno, 602 00, Czechia
  • Brno, 625 00, Czechia
  • Ceske Budejovice, 37001, Czechia
  • Hradec Kralove, 500 03, Czechia
  • Olomouc, 772 00, Czechia
  • Pisek, 39701, Czechia
  • Plzen, 326 00, Czechia
  • Praha 2, Czechia
  • Tabor, 39003, Czechia
  • Aarhus N, 8200, Denmark
  • Copenhagen, 2100, Denmark
  • Odense C, DK-5000, Denmark
  • Espoo, 02100, Finland
  • Helsinki, 00510, Finland
  • Hyvinkää, 05850, Finland
  • Jyväskylä, 40100, Finland
  • Kuopio, 70100, Finland
  • Oulu, 90100, Finland
  • Turku, 20520, Finland
  • Karlsruhe, Baden-Württemberg 76199, Germany
  • Mannheim, Baden-Württemberg 68165, Germany
  • Erlangen, Bayern 91054, Germany
  • München, Bayern 81675, Germany
  • Aachen, Nordrhein-Westfalen 52074, Germany
  • Köln, Nordrhein-Westfalen 50931, Germany
  • Bernburg, Sachsen-Anhalt 06406, Germany
  • Blankenburg, Sachsen-Anhalt 38889, Germany
  • Dippoldiswalde, Sachsen 01744, Germany
  • Dresden, Sachsen 01307, Germany
  • Jena, Thüringen 07743, Germany
  • Berlin, 10787, Germany
  • Berlin, 12200, Germany
  • Hamburg, 20357, Germany
  • Hamburg, 22587, Germany
  • Kitakyushu, Fukuoka 800-0296, Japan
  • Sapporo, Hokkaido 006-8555, Japan
  • Sapporo, Hokkaido 060-0031, Japan
  • Sapporo, Hokkaido 060-0061, Japan
  • Sapporo, Hokkaido 060-0807, Japan
  • Kawanishi, Hyogo 666-0125, Japan
  • Kanazawa, Ishikawa 920-8530, Japan
  • Kurashiki, Okayama 710-0824, Japan
  • Osakasayama, Osaka 589-8511, Japan
  • Hamamatsu, Shizuoka 430-0929, Japan
  • Bunkyo-ku, Tokyo 113-8431, Japan
  • Minatoku, Tokyo 107-0052, Japan
  • Shinagawa-ku, Tokyo 141-8625, Japan
  • Kumamoto, 861-8520, Japan
  • Nagano, 381-8551, Japan
  • Osaka, 543-0023, Japan
  • Almere, Netherlands
  • Groningen, 9700 RB, Netherlands
  • Nieuwegein, 3435 CM, Netherlands
  • Zwolle, 8025 AB, Netherlands
  • Asker, 1383, Norway
  • Stokmarknes, 8450, Norway
  • Tromsø, 9019, Norway
  • Trondheim, 7006, Norway
  • Tønsberg, 3111, Norway
  • Bialystok, 15- 224, Poland
  • Katowice, 40-724, Poland
  • Krakow, 31-121, Poland

Showing the first 100 of 117 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2014 to primary completion in Oct 2016, 24 months.

Results were first posted in Jan 2018, 1 year 2 months after primary completion. A results delay was requested in Jan 2017.

Of 44 phase 2 interventional studies under Endometriosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 37. This study's 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2014
First posted
Jul 29, 2014
StartActual
Oct 16, 2014
Primary completionActual
Oct 24, 2016
CompletionActual
Oct 24, 2016
Results delay requested
Jan 5, 2017
Results first posted
Jan 4, 2018
Last update
Nov 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02203331
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Jul 29, 2014
Start date
Oct 16, 2014
Primary completion
Oct 24, 2016
Completion
Oct 24, 2016
Results posted
Jan 4, 2018
Last update
Nov 7, 2023

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levonorgestrel · Anastrozole

Start the discussion